PROK - PROKIDNEY CORP.
IEX Last Trade
1.69
0.060 3.550%
Share volume: 9,937
Last Updated: Fri 27 Dec 2024 08:30:37 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
0.25%
PREVIOUS CLOSE
CHG
CHG%
$1.63
0.06
3.68%
Fundamental analysis
4%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
10%
Performance
5 Days
6.51%
1 Month
-2.70%
3 Months
-3.23%
6 Months
-25.62%
1 Year
-15.09%
2 Year
-70.73%
Key data
Stock price
$1.69
DAY RANGE
$1.63 - $1.75
52 WEEK RANGE
$1.23 - $4.44
52 WEEK CHANGE
$1.12
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/14/2024
Company detail
CEO: Timothy A. Bertram
Region: US
Website: prokidney.com
Employees: 3
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: prokidney.com
Employees: 3
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
ProKidney Corp., a clinical-stage biotechnology, engages in developing cellular therapy candidates. It is developing Renal Autologous Cell Therapy, an autologous homologous cell admixture that is in a Phase III development program, as well as Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease; and Phase I clinical trial for patients with congenital anomalies of the kidney and urinary tract. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.
Recent news